InVivo Therapeutics Holdings Corporation (NVIVQ) Stock

About InVivo Therapeutics Holdings Corporation

InVivo Therapeutics Holdings Corp. is a U.S.-based biotechnology and biomaterials company, engaged in both research and clinical development. The company's primary focus is on pioneering and commercializing biopolymer scaffolding devices specifically designed for the treatment of spinal cord injuries (SCI). Its flagship product under development is the Neuro-Spinal Scaffold implant, which is constructed from a blend of biocompatible and bioresorbable polymers. These polymers include Poly lactic-co-glycolic acid (PLGA), a material frequently found in dissolvable sutures that provides crucial biocompatible support for the scaffold, and Poly-L-Lysine, a positively charged polymer used to encourage cellular attachment. Founded in 2003, InVivo Therapeutics maintains its headquarters in Cambridge, Massachusetts.

InVivo Therapeutics Holdings Corporation is headquartered in US.

InVivo Therapeutics Holdings Corporation (NVIVQ) stock trades at $0.37 with a market capitalization of $1.15M. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of 0.03, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.15 and $1.41, and currently trades 73.8% below its 52-week high.

On profitability, InVivo Therapeutics Holdings Corporation generates a return on equity (ROE) of -60.12%, return on capital employed of -65.12%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.invivotherapeutics.com